From today, the Australian government will expand Pharmaceutical Benefits Scheme (PBS) access to the drug Keytruda for three ...
Keytruda did not significantly impact long-term health-related quality of life in stage 3 melanoma patients compared to placebo. Both Keytruda and placebo groups returned to baseline quality of life ...
Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The phase 3 ASCENT ...
What Is It, and Why Does It Matter? The FDA has approved a new combination therapy for adults with epithelial cancers that start in the ovaries, fallopian tubes, or lining of the abdomen (peritoneum).